All Stories

  1. Differential systemic inflammatory responses after TAVI: The role of self versus balloon expandable devices
  2. A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model
  3. Elevated Levels of Eotaxin-2 in Serum of Fibromyalgia Patients
  4. Regulatory T cells influence blood flow recovery in experimental hindlimb ischaemia in an IL-10-dependent manner
  5. Circulating Autoantibodies to Endothelial Progenitor Cells: Binding Characteristics and Association with Risk Factors for Atherosclerosis
  6. Autoantibodies to Oxidized Low-Density Lipoprotein in Patients with Aortic Regurgitation: Association with Aortic Diameter Size
  7. Low Levels of Low-Density Lipoprotein Cholesterol: A Negative Predictor of Survival in Elderly Patients with Advanced Heart Failure
  8. Inhibition of monocyte chemotaxis by VB-201, a small molecule lecinoxoid, hinders atherosclerosis development in ApoE−/− mice
  9. Circulating Progenitor and Apoptotic Progenitor Cells in Patients With Aortic Regurgitation
  10. Circulating endothelial cells, plaque rupture and acute coronary syndromes
  11. Islet-1 gene delivery improves myocardial performance after experimental infarction
  12. Regulatory T cells and IL-10 levels are reduced in patients with vulnerable coronary plaques
  13. The “Obesity Paradox”: Does It Persist Among Israeli Patients With Decompensated Heart Failure? A Subanalysis of the Heart Failure Survey in Israel (HFSIS)
  14. Thoracic aortic atherosclerosis in patients with aortic regurgitation
  15. Ras Inhibition Induces Insulin Sensitivity and Glucose Uptake
  16. Usefulness of Total Lymphocyte Count as Predictor of Outcome in Patients With Chronic Heart Failure
  17. Modified phospholipids as anti-inflammatory compounds
  18. Ras inhibition attenuates pancreatic cell death and experimental type 1 diabetes: Possible role of regulatory T cells
  19. Time to rheology in acute myocardial infarction: inflammation and erythrocyte aggregation as a consequence and not necessarily as precursors of the disease
  20. Enhanced adhesive properties of endothelial progenitor cells (EPCs) in patients with SLE
  21. The Ras antagonist farnesylthiosalicylic acid ameliorates experimental myocarditis in the rat
  22. Baseline Low-Density Lipoprotein Cholesterol Levels and Outcome in Patients With Heart Failure
  23. Fewer Circulating Endothelial Progenitor Cells in Newly Diagnosed Neovascular AMD Patients
  24. B-Type Natriuretic Peptide Enhances Vasculogenesis by Promoting Number and Functional Properties of Early Endothelial Progenitor Cells
  25. Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice
  26. Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice
  27. Antiphospholipid antibodies from a patient with primary antiphospholipid syndrome enhance experimental atherosclerosis
  28. Hypoxia-Inducible Factor-1α and -2α Additively Promote Endothelial Vasculogenic Properties
  29. Whole-body hyperthermia attenuates experimental autoimmune myocarditis in the rat
  30. Circulating Apoptotic Progenitor Cells in Patients with Congestive Heart Failure
  31. Hypoxia controls CD4+CD25+ regulatory T‐cell homeostasis via hypoxia‐inducible factor‐1α
  32. Circulating endothelial progenitor cells in cardiovascular disorders
  33. Normal levels and function of endothelial progenitor cells in patients with psoriatic arthritis
  34. Mechanisms of Disease: the evolving role of regulatory T cells in atherosclerosis
  35. N‐Ras or K‐Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells
  36. Treatment of Post-Catheterization Femoral Artery Pseudo-Aneurysm With Para-Aneurysmal Saline Injection
  37. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells
  38. Predictive value of high sensitivity CRP in patients with diastolic heart failure
  39. Endothelial progenitor cells as therapeutic vectors in cardiovascular disorders: From experimental models to human trials
  40. Autoantibodies to cardiac troponin I in patients with idiopathic dilated and ischemic cardiomyopathy
  41. Effect of anti-TNFα treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis
  42. Comparative Analysis of Methods for Assessment of Circulating Endothelial Progenitor Cells
  43. Comparative Analysis of Methods for Assessment of Circulating Endothelial Progenitor Cells
  44. Cellular autoimmunity to cardiac myosin in patients with a recent myocardial infarction
  45. The role of erythropoietin in myocardial protection: potential mechanisms and applications
  46. Serum levels of anti heat shock protein 70 antibodies in patients with stable and unstable angina pectoris
  47. Usefulness of anti‐oxidized LDL antibody determination for assessment of clinical control in patients with heart failure
  48. Circulating Erythropoietin Levels and Prognosis in Patients With Congestive Heart Failure
  49. The effect of tyrphostin AG-556 on intimal thickening in a mouse model of arterial injury
  50. Temporal association between circulating proteolytic, inflammatory and neurohormonal markers in patients with coronary ectasia
  51. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis
  52. Association Between Circulating Early Endothelial Progenitors and CD4+CD25+ Regulatory T Cells: A Possible Cross-talk between Immunity and Angiogenesis?
  53. Serum levels of interleukin-18 in patients with stable and unstable angina pectoris
  54. Antigen-tailored therapy based on the inflammatory theory of atherosclerosis
  55. Suppression of myosin-induced and adoptively transferred myocarditis by prior treatment with complete Freund's adjuvant
  56. l-Arginine attenuates lymphocyte activation and anti-oxidized LDL antibody levels in patients undergoing angioplasty
  57. The effect of early and late treatment with the tyrphostin AG-556 on the progression of experimental autoimmune myocarditis
  58. Evidence for the involvement of T cell costimulation through the B-7/CD28 pathway in atherosclerotic plaques from apolipoprotein E knockout mice
  59. 867-1 A functional role for inducible costimulator in atherosclerosis
  60. 803-1 The number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis
  61. 1103-196 Circulating endothelial progenitor cells in patients with unstable angina: Association with systemic inflammation
  62. Eptifibatide does not influence lymphocyte activation and CRP levels in patients with undergoing coronary angioplasty
  63. Stent thrombosis in patients treated with thienopyridines: clinical description of 10 cases
  64. Tyrphostin AG-556 reduces myocardial infarct size and improves cardiac performance in the rat
  65. Immunity to heat shock protein 65—an additional determinant in intimal thickening
  66. Oral tolerance with heat shock protein 65 attenuates mycobacterium tuberculosis-inducedand high-fat-diet-driven atherosclerotic lesions
  67. The effect of intravenous immunoglobulins on intimal thickening in a mouse model of arterial injury
  68. Accelerated intimal thickening in carotid arteries of balloon-injured rats after immunization against heat shock protein 70
  69. β2-Glycoprotein I and atherosclerosis
  70. Cellular and humoral immune responses to heat shock protein 65 are both involved in promoting fatty-streak formation in LDL-receptor deficient mice
  71. Non-obese diabetic (NOD) mice exhibit an increased cellular immune response to glycated-LDL but are resistant to high fat diet induced atherosclerosis
  72. ACCELERATED ATHEROMA, ANTIPHOSPHOLIPID ANTIBODIES, AND THE ANTIPHOSPHOLIPID SYNDROME
  73. The Effect of Intravenous Immunoglobulins on the Progression of Experimental Autoimmune Myocarditis in the Rat
  74. Atherosclerosis
  75. Interleukin (IL)-4 deficiency does not influence fatty streak formation in C57BL/6 mice
  76. Heat Shock Protein 60/65, β2-glycoprotein I and Oxidized LDL as Players in Murine Atherosclerosis
  77. Anti-endothelial cell antibodies in patients with coronary atherosclerosis
  78. The effects of N-6 polyunsaturated fatty acid supplementation on the lipid composition and atherogenesis in mouse models of atherosclerosis
  79. The prediction of coronary atherosclerosis employing artificial neural networks
  80. Intravenous immunoglobulin treatment of lupus nephritis
  81. Immunization of Low-density Lipoprotein Receptor Deficient (LDL-RD) Mice with Heat Shock Protein 65 (HSP-65) Promotes Early Atherosclerosis
  82. The Smoking Cancer—Autoimmunity Connection
  83. The Involvement of β2-Glycoprotein I (β2-GPI) in Human and Murine Atherosclerosis
  84. Anti-oxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty
  85. Use of Intravenous Immunoglobulin in Idiopathic Membranous Nephropathy
  86. Serologic and Clinical Response to Treatment of Systemic Vasculitis and Associated Autoimmune Disease with Intravenous Immunoglobulin
  87. Enhancement of Atherosclerosis in Beta-2-Glycoprotein I-Immunized Apolipoprotein E-Deficient Mice
  88. Functional properties of antiendothelial cell antibodies
  89. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation
  90. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis
  91. Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin‐3 and granulocyte‐macrophage colony‐stimulating factor expression
  92. Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin-3 and granulocyte-macrophage colony-stimulating factor expression
  93. BCG
  94. Hantavirus Seropositivity in Israeli Patients with Renal Failure
  95. Emerging cross-regulatory roles of immunity and autoimmunity in atherosclerosis
  96. The effects of early and late administration of M-20 derived interleukin-1 inhibitor on experimental systemic lupus erythematosus
  97. Actin Autoantibodies
  98. Natural Autoantibodies
  99. Hidden Autoantibodies
  100. Immune Network and Autoimmunity.
  101. Guillain-Barré as an Autoimmune Disease
  102. Anti-actin antibodies in sera from patients with autoimmune liver diseases and patients with carcinomas by ELISA